Xenome gets acute
Wednesday, 19 November, 2008
Private Brisbane biotech Xenome has expanded its protein chemistry portfolio by licensing peptide technology from Flinders University.
The IP relates to two peptides identified by Flinders researchers as candidates for blocking cell surface receptors involved in acute pancreatitis.
The receptors are activated by the peptide galanin, normally involved in the regulation of the release of neurotransmitters and hormones.
Xenome, which is in early stage trials of cone shell based venom peptides for acute and chronic pain, will pay Flinders milestone payments and royalties. It plans to modify the structure of the peptides to develop their capabities as drug candidates.
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
Mediterranean-style diet benefits maternal and infant health
Two studies have found that a Mediterranean-style diet benefits maternal health during pregnancy...
Genes play an active role in gut health, researchers find
It appears that genes play an active role in shaping bacterial communities, putting into question...
